[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

[IP] Fw: [Fwd: needleless injection device developed]

-----Original Message-----
From: Ignace HINDRICK <email @ redacted>
To: Diabetes-List <email @ redacted>
Date: Sunday, December 21, 1997 5:56 AM
Subject: [Fwd: needleless injection device developed]


-- BEGIN included message

               Needleless Injection Device Developed

               CORONADO, CA -- December 18, 1997 -- Genetronics Biomedical Ltd.
               announced this week at the International Conference on Transdermal Drug
               Delivery that it has developed a prototype for a palm-sized, hand-held
               transdermal device for quick and efficient delivery of pharmaceuticals or
               beneficial genes.

               Lei Zhang, Ph.D., staff scientist and project manager for transdermal drug
               delivery at Genetronics, said the new transdermal device will deliver drugs or
               genes without the patient having to wear the device.

               One of the significant technical problems involving the transdermal delivery of
               drugs is that the stratum corneum, the skin's outer layer, forms a
               highly-protective barrier against physical, chemical, or other penetrations.

               Consequently, transdermal delivery has been limited to potent drugs that
               naturally penetrate the skin. Large molecule, synthetic drugs, as well as peptides
               and proteins, have proven much more difficult to deliver via traditional
               transdermal methods. To resolve this problem, Genetronics has developed a
               prototype generator that utilizes electroincorporation to deliver drugs or genes
               through the outer layer of skin.

               Electroincorporation, a variation of Genetronics electroporation technology and
               a patented process developed by Genetronics, involves using pulsed electric
               fields to transport drugs and genes into the skin or the bloodstream for topical or
               systemic delivery. Liposomes, microspheres and biodegradable particles are the
               most effective formulations to use in conjunction with this needleless injection of

               Genetronics is currently conducting human trials for the topical delivery of
               lidocaine in healthy volunteers by electroporation at the University of California
               at San Diego Pain Management Center. 

               The potential uses of the technology are numerous and in conditions ranging from
               diabetes to psoriasis and baldness. Genetronics is focusing on several
               transdermal applications that have a large potential market, such as pain
               management (acute and chronic), erectile dysfunction and skin aging. 

-- END included message